News
Keytruda beats Opdivo to first-line oesophageal cancer OK in...
Merck & Co's Keytruda has become the first cancer immunotherapy to be approved as a first-line oesophageal cancer therapy in the EU, ahead of Bristol-Myers Squibb's rival Opdivo, but BM
